Abstract:
In this paper BuzzMetrics reviews findings from analyses of online consumer buzz for two sets of promising drug therapies. The therapies with pre-approval buzz experienced an enormous increase in discussion among relevant online communities versus those that had little or no pre-approval buzz. This suggests the value of a pharma brand's investment in even a small amount of pre-launch buzz.
